Adicet Bio, Inc. (ACET) AI Stock Analysis

Headquartered in Boston, Massachusetts, Adicet Bio, Inc. specializes in the discovery and development of allogeneic gamma delta T cell therapies designed to combat cancer and other diseases. The company engineers gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies to enhance tumor targeting, activate anti-tumor immune responses, and promote prolonged therapeutic efficacy. Its lead product candidate, ADI-001, is in Phase I clinical trials for the treatment of non-Hodgkin's lymphoma. Adicet Bio is also developing ADI-002, a preclinical asset aimed at various solid tumors, and pursues strategic partnerships across the biopharmaceutical sector.

Adicet Bio reported trailing twelve month revenue of $0 as of June 30, 2026, with quarterly revenue falling 100.0% year-over-year. Historically, annual revenue rose from $8.2M in FY2018 to $25.0M in FY2022, though five-year revenue CAGR from FY2017 to FY2022 was -46.3%. Operating losses expanded over that period, with operating margin at -290.3% and net income reaching -$69.8M in FY2022. R&D spending climbed from $14.7M in FY2018 to $71.2M in FY2022. Diluted EPS was -$16.56 in FY2022 and -$10.42 for the trailing twelve months, reflecting development-stage losses and an operating margin of 0.0%.

As of June 30, 2026, Adicet Bio held $118.2M in cash and short-term investments against total debt of $12.9M, resulting in net cash of $105.3M. The company maintains a current ratio of 6.71 and a debt-to-equity ratio of 0.11 on shareholders' equity of $120.1M. Capital expenditures for FY2025 totaled $1.7M, while free cash flow was -$61.5M in FY2022. Over a five-year period, the share count increased by 407.0%.

At $4.57 per share, Adicet Bio has a market capitalization of $42.8M and an enterprise value of -$26.4M. Its price-to-sales ratio is 9.7x, compared to 4.1x for the median of its US-listed Healthcare peers. Adicet trades at a price-to-book ratio of 0.7x and has an EV-to-revenue ratio of 2.1x. Over the past year, ACET stock fell 72.5%, underperforming the S&P 500 (SPY) return of 16.8%. Over five years, the stock dropped 96.4% while the S&P 500 gained 83.0%.

Wall Street coverage consists of 6 Strong Buy ratings, with zero Buy, Hold, Sell, or Strong Sell recommendations. The mean price target of $34.83 implies an upside of 662.2% from the last close of $4.57. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$6.36 and $0 in revenue. For the next fiscal year, 6 analysts project an EPS of -$4.04 on revenue of $28.5M. Adicet beat EPS estimates in 2 of the last 4 quarters, with next earnings scheduled for November 4, 2026.

This page is an AI-written research summary of Adicet Bio, Inc. (ACET). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ACET income statement, ACET balance sheet, ACET key metrics, ACET analyst forecast, ACET chart. See the ACET stock overview for the latest quote and news.